{"id":"hb0025","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, HB0025 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"HB0025 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:38.571Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07383116","phase":"PHASE3","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-01-15","conditions":"Non Squamous Non-small Cell Lung Cancer","enrollment":500},{"nctId":"NCT07376629","phase":"PHASE2","title":"A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC","status":"ENROLLING_BY_INVITATION","sponsor":"Huabo Biopharm Co., Ltd.","startDate":"2025-08-14","conditions":"TNBC","enrollment":60},{"nctId":"NCT07360132","phase":"PHASE3","title":"Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Huaota Biopharmaceutical Co., Ltd.","startDate":"2026-01-15","conditions":"Squamous Non-small Cell Lung Cancer","enrollment":480},{"nctId":"NCT06758557","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor","status":"RECRUITING","sponsor":"Huabo Biopharm Co., Ltd.","startDate":"2024-01-31","conditions":"Advanced NSCLC, Advanced Endometrial Cancer","enrollment":282},{"nctId":"NCT06222125","phase":"PHASE2","title":"A Study of HB0025 Injection in Patients With Advanced Renal Cancer","status":"UNKNOWN","sponsor":"Huabo Biopharm Co., Ltd.","startDate":"2023-01-30","conditions":"Renal Cancer","enrollment":100},{"nctId":"NCT04678908","phase":"PHASE1","title":"A Study of Injection HB0025 in Patients With Advanced Solid Tumors","status":"UNKNOWN","sponsor":"Huabo Biopharm Co., Ltd.","startDate":"2021-03-10","conditions":"Tumor, Subjects","enrollment":154}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Recombinant Humanized Anti-PD-L1 Monoclonal Antibody-VEGFR1 Fusion Protein","Recombinant humanized anti-programmed cell death-ligand 1（Anti-PD-L1） monoclonal antibody-VEGFR1 fusion protein"],"phase":"phase_3","status":"active","brandName":"HB0025","genericName":"HB0025","companyName":"Huabo Biopharm Co., Ltd.","companyId":"huabo-biopharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HB0025 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}